- Home
- TDAC vs YMAB Comparison
TDAC vs YMAB Comparison
Compare TDAC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDAC
- YMAB
- Stock Information
- Founded
- TDAC 2022
- YMAB 2015
- Country
- TDAC United States
- YMAB United States
- Employees
- TDAC N/A
- YMAB N/A
- Industry
- TDAC
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TDAC
- YMAB Health Care
- Exchange
- TDAC NYSE
- YMAB Nasdaq
- Market Cap
- TDAC 221.0M
- YMAB 192.4M
- IPO Year
- TDAC 2024
- YMAB 2018
- Fundamental
- Price
- TDAC N/A
- YMAB $4.30
- Analyst Decision
- TDAC
- YMAB Buy
- Analyst Count
- TDAC 0
- YMAB 11
- Target Price
- TDAC N/A
- YMAB $17.55
- AVG Volume (30 Days)
- TDAC 17.0K
- YMAB 204.2K
- Earning Date
- TDAC 01-01-0001
- YMAB 08-11-2025
- Dividend Yield
- TDAC N/A
- YMAB N/A
- EPS Growth
- TDAC N/A
- YMAB N/A
- EPS
- TDAC 0.16
- YMAB N/A
- Revenue
- TDAC N/A
- YMAB $88,658,000.00
- Revenue This Year
- TDAC N/A
- YMAB N/A
- Revenue Next Year
- TDAC N/A
- YMAB $15.15
- P/E Ratio
- TDAC $160.48
- YMAB N/A
- Revenue Growth
- TDAC N/A
- YMAB 4.92
- 52 Week Low
- TDAC $10.00
- YMAB $3.55
- 52 Week High
- TDAC $10.29
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- TDAC N/A
- YMAB 42.53
- Support Level
- TDAC N/A
- YMAB $3.90
- Resistance Level
- TDAC N/A
- YMAB $5.33
- Average True Range (ATR)
- TDAC 0.00
- YMAB 0.36
- MACD
- TDAC 0.00
- YMAB -0.08
- Stochastic Oscillator
- TDAC 0.00
- YMAB 27.97
About TDAC TRANSLATIONAL DEVELOPMENT ACQUISITI
Translational Development Acquisition Corp is a newly organized blank check company.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.